Scroll Top

Blog

noticia2
23 de June, 2023
FDA Approves LITFULO™ (Ritlecitinib) for Adults and Adolescents with Severe Alopecia Areata

Today, the United States Food and Drug Administration (FDA) approved LITFULO™ for severe alopecia areata, marking the second FDA-approved treatment for this disease and the first approved for children 12 years and older. “The National Alopecia Areata Foundation is thrilled to have a second FDA-approved treatment for alopecia areata, the first approved for adolescents. We continue to see tangible results from the initial efforts of our Treatment Development Program to lay the scientific groundwork for these advancements,” said Nicole Friedland, NAAF President and CEO. “We remain committed to supporting more discoveries and empowering our community with more options.” LITFULO™ (ritlecitinib) belongs to a class of medicines known as janus kinase inhibitors (JAK). LITFULO™ is FDA-approved for adults and children 12 years and older with severe alopecia areata. LITFULO™, manufactured by Pfizer Inc., is available only with a prescription.

The National Alopecia Areata Foundation (NAAF) supports research to find a cure or acceptable treatment for alopecia areata, supports those with the disease, and educates the public about alopecia areata. Alopecia areata is a common autoimmune disease that affects nearly 7 million Americans and results in total or partial hair loss on the scalp and body. Founded in 1981 and headquartered in San Rafael, CA, NAAF is widely recognized as the largest alopecia areata advocacy organization in the United States. NAAF connects with the alopecia areata community, including patients, family members, healthcare professionals and researchers, through its support programs, email newsletters, website, research summits and annual patient conference. NAAF is a 501(c)(3) nonprofit and a Candid Platinum-Rated charity, meeting the rigorous standards of the Better Business Bureau Wise Giving Alliance and the National Health Council.

Read Pfizer’s press release here.

Entraremos em contacto brevemente

This site is registered on wpml.org as a development site.